|  |  |  |
| --- | --- | --- |
| COUNTRY | Authorization date | Indication(s) |
| United States | 19 May 2009 | SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). |
| Europe\* | 03 Aug 2009 | Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). |
| 27 May 2015 | Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. |
| Hong Kong | 06 Aug 2010 | SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and SIADH. |
| Japan | 27 Oct 2010 | Volume overload in heart failure when adequate response is not obtained with other diuretics (eg, loop diuretics). |
| 13 Sep 2013 | Body fluid retention in hepatic cirrhosis when adequate response is not obtained with other diuretics (e.g., loop diuretics) |
| 24 Mar 2014 | Suppression of progression of autosomal dominant polycystic kidney disease (ADPKD) in patients with increased kidney volume and a rapid rate of increase |
| Taiwan | 23 Nov 2010 | SAMSCA is indicated for the treatment of patients with hyponatremia secondary to heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). |
| Canada | 25 Jul 2011 | SAMSCA (tolvaptan) is indicated for the treatment of clinically important, non-hypovolemic hyponatremia, (e.g., serum sodium < 130 mEq/L, or symptomatic hyponatremia). |
| 25-Feb-2015 | JINARC™ (tolvaptan) is indicated to slow the progression of kidney enlargement in patients with autosomal dominant polycystic kidney disease (ADPKD). In ADPKD, kidney enlargement reflects renal cyst burden. |
| Republic of Korea | 01 Sep 2011 | Treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) and etc. |
| 01 Dec 2015 | To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. |
| China | 23 Sep 2011 | Tolvaptan is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction], including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). |
| Indonesia | 01 Nov 2011 | Treatment of adult patients with hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).  Treatment of clinically significant hypervolemic hyponatremia that has resisted correction with fluid restriction (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic in patients with heart failure.) |
| Australia | 15 Mar 2012 | SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mmol/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). |
| Turkey | 31 Jul 2012 | The treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) |
| 26 Jul 2015 | SAMSCA is indicated for the treatment of volume overload in heart failure when adequate response is not obtained with other diuretics (e.g., loop diuretics). |
| Philippines | 03 Jun 2013 | TOLVAPTAN (SAMSCA®) is indicated for the treatment of clinically significant  hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked  hyponatremia that is symptomatic and has resisted correction with fluid restriction), including  patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).  Volume overload in heart failure when adequate response is not obtained with other diuretics  (e.g., loop diuretics) |
| Thailand | 25 Dec 2013 | SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).  Volume overload in heart failure when adequate response is not obtained with other diuretics (e.g., loop diuretics). |
| Switzerland | 21 Apr 2016 | Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults who have CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. |

\*Europe (EU/EEA): Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom